Sunday, January 23, 2022

Dr. Peter McCullough: Vaccines Failed in Stopping COVID-19 and Mandates Have to Be Dropped

“The vaccines themselves have basically now become obsolete as the virus has continued to mutate,” McCullough told NTD’s “Capitol Report” in an interview broadcast on Wednesday. “So at this point of time, the vaccine mandates have to be dropped across the board.”

McCullough said some recent studies have shown the effectiveness of the COVID-19 vaccines dropped significantly with the new variants.

“There’s a paper by Young-Xu in JAMA, the prior Delta strain that was only about 20 percent covered by the vaccines. Vaccines were very ineffective against Delta,” McCullough said.

The study, which is peer-reviewed and published on the Journal of the American Medical Association (JAMA) last month, found that during the high-Delta period, the estimated vaccine effectiveness was 62.0 percent in the first month and decreased to 57.8 percent by month three. The decrease in vaccine effectiveness accelerated after month four, reaching a low of approximately 20 percent in months five through seven.

“And now a paper from Hansen from Denmark, and from the UK public health security report indicated, against Omicron the vaccines are basically ineffective,” McCullough continued.

The Danish study, a preprint and has not been peer-reviewed, found that vaccine effectiveness against Omicron was initially 55.2 percent and 36.7 percent for Pfizer and Moderna vaccines, respectively, but waned rapidly over time. By comparison, vaccine effectiveness against Delta was significantly higher and better preserved over the same period.

The UK Health Security Agency report released on Dec. 31 also found that vaccine effectiveness against the Omicron variant is significantly lower than compared to the Delta variant and wanes rapidly.

“Among those who had received 2 doses of AstraZeneca, there was no effect against Omicron from 20 weeks after the second dose. Among those who had received 2 doses of Pfizer or Moderna, effectiveness dropped from around 65 to 70 percent down to around 10 percent by 20 weeks after the second dose,” the report (pdf) states.

The Centers for Disease Control and Prevention (CDC) has been saying the COVID-19 vaccines are “safe and effective,” and serious adverse events are rare.

“The only thing the vaccines could have done is reduce the chances of getting COVID-19. … So many millions of Americans who have taken the vaccines have been disappointed to find out they contracted COVID-19 anyway,” McCullough continued.

On Wednesday, the CDC published a study showing protection from prior infection, or so-called natural immunity, was better than the protection from COVID-19 vaccines against the Delta variant.

McCullough also said the vaccine mandates lack the ethical or legal standing in the first place because the COVID-19 vaccines are “investigational.”

“All the vaccines are still investigational and in research. Mandates had no ethical or moral or legal standing from that perspective. No one can be forced into research against their will or be coerced into it.”

A spokesperson from the Food and Drug Administration (FDA), didn’t answer directly whether COVID-19 vaccines are investigational, but told The Epoch Times that “all of the vaccines are under an EUA except for Comirnaty, which is fully approved.”

In a guidance (pdf) issued last year, FDA said emergency use authorizations (EUAs) are issued for investigational vaccines to prevent COVID-19 during the pandemic.

“We can’t have Americans have fear about losing their job or school or travel related to a failed vaccine,” McCullough said. “But even more so we need to re-examine what we’ve done with respect to our public health priorities and COVID-19.”

McCullough said that in March and April 2020 America should have had large randomized trials and moved very quickly into studying multi-drug treatment. However, the federal authorities refused to do so and made a big push for vaccines.

McCullough also shared the treatment for COVID-19 patients with the Omicron variant.

“Fortunately with the Omicron variants very mild, the main treatment is oral nasal virucidal washes with dilute povidone-iodine or hydrogen peroxide 12. Clinical trials show the biggest benefit of that is more than any other form of treatment,” McCullough said.

Occasionally patients may need additional oral drugs and Pfizer and Merck pills could be featured, the renowned cardiologist and epidemiologist added.

“And for severe cases we can use Sotrovimab, which is the GSK monoclonal antibody, may be in a high-risk senior or special case,” McCullough said.

“The vaccines aren’t treatment, they offered no hope of treating a patient once they contracted COVID-19. And we knew with respiratory virus they were very unlikely to be effective,” said the doctor.

The CDC has been saying that the COVID-19 vaccines could reduce severe illness and death, and vaccinated people should get a booster to keep up the protection.


Olympic Athlete Reveals Chilling Side Effect of COVID Booster

Professional athletes fine-tune their bodies in an effort to be the best in the world — but what happens when something goes wrong with a medical procedure?

That’s the unfortunate position Swiss sprinter and Olympian Sarah Atcho found herself in after having a severe reaction to a COVID-19 booster vaccine.

The 26-year-old who competed in the 2016 and 2020 Olympic Games took to social media on Monday to share her experience with the world, giving a matter-of-fact account of a possibly life-changing event.

“Obviously as you know, I’m trying to be as transparent as I can and now is more important than ever,” she began her lengthy post.

“On December 22 I got my booster vaccination because I didn’t want to struggle with this when the season started. I was told that it was safer to get Pfizer (even though I had Moderna the first time) to avoid cardiac side effects,” she wrote.

A recent study found that Moderna’s vaccine is four times more likely to cause heart inflammation than Pfizer’s. Sweden and Finland have both halted its use.

“On December 27 I felt a tightness in the chest and started feeling dizzy while walking up the stairs,” the young athlete continued.

“This happened a few more times until I decided to check with a cardiologist who diagnosed me with pericarditis (inflammation of the thin membrane surrounding the heart).”

Atcho went on to say she would have to take time off from activities that increased her heart rate.

“I have to admit that I am upset at the situation because we don’t talk enough about the side effects. I feel helpless since this is completely out of my control,” Atcho disclosed.

“I am glad the vaccine helped avoid many deaths and reduce the pressure on the hospitals and hospital staff however I am frustrated that myself as well as other young and healthy people are suffering from these heavy side effects,” she added.

There have been other anecdotal accounts of young athletes experiencing serious side effects such as myocarditis and pericarditis after receiving COVID-19 vaccines, but officials still insist this occurrence is rare.

Of course, it’s hard to tell, since even talking about vaccine side effects or expressing skepticism about the jab is enough to get a person de-platformed.

Dr. Robert Malone, who was instrumental in inventing the mRNA technology used in the COVID-19 vaccines, was thrown off Twitter for expressing his concerns that the vaccines may be doing more harm than good.

Regardless of whether Malone is correct or not, any treatment or procedure should be able to withstand the scrutiny that comes with speaking about its potential side effects.

Perhaps Atcho is a one-in-a-million case — who knows? But the fact that vaccine injury is a subject too taboo to discuss in public raises major red flags.


New sub-variant of Omicron under investigation as it sweeps Europe

A new sister subtype of the Covid Omicron variant, which may be more transmissible and harder to track, has begun rearing its head overseas in recent days.

The subtype is being referred to as BA. 2, while the original Omicron, currently sweeping through Australia, is known by scientists as BA. 1.

While cases of the BA. 2 type of Omicron remain low across various European countries, it could be just a matter of time before it arrives in Australia.

Scientists are still however working to determine whether the subtype, which had infected 53 people in the UK up to January 10, is more severe than the original BA. 1 type.

While the Health Security Agency has designated BA. 2 as a variant under investigation, its UK incident director Dr Meera Chand said such subtypes were to be expected.

“It is the nature of viruses to evolve and mutate, so it’s to be expected that we will continue to see new variants emerge,” she said, according to Metro.

There had been early indications the BA. 2 type may be more transmissible than BA. 1, however in Denmark, where it accounts for about half of Omicron cases, no stark differences in hospitalisations had yet been noted.

Denmark’s Statens Serum Institute this week said it was likely vaccines had an effect against severe BA. 2 infections, which had several differences to BA.1.

One difference was that BA. 2 had shown positive for the S-gene, while BA. 1 did not.

The lack of S-gene in BA. 1 was a key component in tracking Omicron’s early spread, as it was a feature that distinguished it from Delta.

The same feature however may be what makes BA. 2 infections harder to track.

Scientists are still confident it will be picked up in certain tests though.

Virologist from the Imperial College of London, Tom Peacock, said while early trends suggested BA. 2 was more transmissible, more research was required.

“BA. 2 appears to be the major Omicron lineage in (part of) India and the Philippines and there is evidence it is growing compared to BA. 1 in Denmark, the UK and Germany,” one recent tweet read.

“Consistent growth across multiple countries is evidence BA. 2 may be some degree more transmissible than BA.1. This is the main reason BA. 2 is currently in the news.

“Unfortunately this is really where the evidence mostly ends – we do not currently have a strong handle on antigenicity, severity or a much evidence for how much more transmissibility BA. 2 might have over BA. 1 – however we can make some guesses/early observations.”

He added how “very early observations” from India and Denmark suggested there was no dramatic difference in severity when compared to BA.1.

“This data should become more solid (one way or another) in the coming weeks,” he said.

Mr Peacock also predicted BA. 2 would not have a “substantial” impact on the Omicron wave, which he expected was past its peak already in many countries.




No comments: